Vnitr Lek 2004, 50(Supplement 1):S71-S75

[Dyslipidemia at the turn of the century: optimism or scepticism?].

V Soska: Centrum pro diagnostilku a lécbu dyslipidemií, Oddelení klinického komplementu FN u sv. Anny, Brno.

Treatment of dyslipidaemia is one of the most important factors that decreases cardiovascular mortality and morbidity. Although we know lipid levels goals, we are not very successful in achiving them. The number of hypolipidemic substances is increasing and we have got guidelines for treatment dyslipidaemic patients. It is very important to implement this guidelines in the clinical practice. Another problem is rather poor patients's compliance both for dyslipidaemia treatment and for lifestyle changes. Pharmacologic treatment of dyslipidaemia may be limited due to its high expense. Pharmacologic treatment thus should be target to the high risk population: patients with coronary heart disease, patients with diabetes mellitus and with familial hypercholesterolaemia. In primary prevention only persons with high risk of cardiovascular event should be treated with hypolipidemic drugs.